[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-567722-105":53,"doc-detail-567722-en":126},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":119,"head_meta":121,"extra_data":123,"updated_unix":125},105,"en","cytopoint-10-mg-solution-for-injection-for-dogs-package-and-leaflet-minimum-particulars-revised-january-2025","CYTOPOINT 10 mg solution for injection for dogs - Package and leaflet minimum particulars - Revised January 2025","","CYTOPOINT 10 mg solution for injection (lokivetmab) for dogs provides minimum particulars for the outer package, small immediate packaging units, and the package leaflet. It lists composition per 1 ml dose, target species, indications for pruritus linked to allergic dermatitis and clinical atopic dermatitis manifestations, contraindications, special warnings about anti-drug antibodies, and key precautions for safe use, storage, disposal, dosing effectiveness, and risks from accidental self-injection.",{"@graph":63,"@context":118},[64,80,101],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":36,"@type":70,"position":76},"https://docshare.wps.com/template/forms/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/cytopoint-10-mg-solution-for-injection-for-dogs-package-and-leaflet-minimum-particulars-revised-january-2025/567722/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/cytopoint-10-mg-solution-for-injection-for-dogs-package-and-leaflet-minimum-particulars-revised-january-2025/567722.png","ImageObject",442,249,{"name":88,"@type":89},"pixelkiddo","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-10-15","2026-10-13",true,{"@type":98,"interactionType":99,"userInteractionCount":9},"InteractionCounter",{"@type":100},"ViewAction",{"@type":102,"mainEntity":103},"FAQPage",[104,110,114],{"name":105,"@type":106,"acceptedAnswer":107},"What is the active ingredient and strength in CYTOPOINT 10 mg for dogs?","Question",{"text":108,"@type":109},"Each 1 ml dose contains 10 mg lokivetmab. The leaflet also describes it as a clear to opalescent solution without visible particles.","Answer",{"name":111,"@type":106,"acceptedAnswer":112},"How is CYTOPOINT administered and what are the target species?",{"text":113,"@type":109},"CYTOPOINT is for dogs only and is given by subcutaneous (SC) use. The label specifies subcutaneous use for the outer package and SC for the small immediate packaging unit.",{"name":115,"@type":106,"acceptedAnswer":116},"What are the key warnings and precautions before and during treatment?",{"text":117,"@type":109},"Lokivetmab may induce transient or persistent anti-drug antibodies, potentially reducing efficacy in some dogs. Investigate and treat underlying causes of allergic dermatitis, monitor for bacterial infections during the first weeks, and consider a second dose one month later if response is limited within one month.","https://schema.org",{"og:url":78,"og:type":120,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":122,"canonical":78},"index,follow",{"doc_id":124,"site_id":56},567722,1792107446,{"code":4,"msg":5,"data":127},{"doc_id":124,"user_id":128,"nickname":88,"user_avatar":129,"doc_module":9,"category_id":35,"category_name":36,"doc_title":59,"doc_description":61,"doc_content":130,"file_id":131,"file_url":132,"file_type":133,"file_size":134,"view_count":9,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":135,"language":136,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":137,"faqs":138,"seo_title":139,"seo_description":61,"update_tm":140,"read_time":76},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","Revised: January 2025  \nAN: 03226/2024  \nPARTICULARS TO APPEAR ON THE OUTER PACKAGE {Cardboard Box}  \n1. NAME OF THE VETERINARY MEDICINAL PRODUCT  \nCYTOPOINT 10 mg solution for injection  \n2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES  \nEach 1 ml dose contains 10 mg lokivetmab.  \n3. PACKAGE SIZE  \n1 x 1 ml  \n2 x 1 ml  \n6 x 1 ml  \n4. TARGET SPECIES  \nDogs.  \n5. INDICATIONS  \n6. ROUTES OF ADMINISTRATION  \nSubcutaneous use.  \n7. WITHDRAWAL PERIODS  \n8. EXPIRY DATE  \nExp. {mm/yyyy}  \nOnce broached use immediately.  \n9. SPECIAL STORAGE PRECAUTIONS  \nStore in a refrigerator. Do not freeze.  \nStore in the original package. Protect from light.  \nRevised: January 2025  \nAN: 03226/2024  \n10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”  \nRead the package leaflet before use.  \n11. THE WORDS “FOR ANIMAL TREATMENT ONLY”  \nFor animal treatment only.  \n12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”  \nKeep out of the sight and reach of children.  \n13. NAME OF THE MARKETING AUTHORISATION HOLDER  \nZoetis UK Limited  \n14. MARKETING AUTHORISATION NUMBERS  \nVm 42058/5017  \n15. BATCH NUMBER  \nLot {number}  \n16. SPECIAL WARNING(S), IF NECESSARY  \n17. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY  \nDisposal: Read package leaflet.  \n18. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IF APPLICABLE  \nPOM-V  \nVeterinary medicinal product subject to prescription  \nRevised: January 2025  \nAN: 03226/2024  \nMINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING  \nUNITS {Vial / 1 ml}  \n1. NAME OF THE VETERINARY MEDICINAL PRODUCT  \nCYTOPOINT  \n2. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES  \nlokivetmab 10 mg/ml  \n3. BATCH NUMBER  \nLot {number}  \n4. EXPIRY DATE  \nExp. {mm/yyyy}  \nOnce broached use immediately.  \n5. ROUTE(S) OF ADMINISTRATION  \nSC  \n6. THE WORDS “FOR ANIMAL TREATMENT ONLY”  \nFor animal treatment only.  \nRevised: January 2025  \nAN: 03226/2024  \nPARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:  \n1. NAME OF THE VETERINARY MEDICINAL PRODUCT  \nCYTOPOINT 10 mg solution for injection for dogs  \n2. COMPOSITION  \nEach 1 ml dose contains:  \nActive substance:  \nLokivetmab* 10 mg  \n*Lokivetmab is a caninised monoclonal antibody expressed through recombinant techniques in Chinese hamster ovary (CHO) cells  \nClear to opalescent solution without any visible particles.  \n3. TARGET SPECIES  \nDogs.  \n4. INDICATIONS FOR USE  \nTreatment of pruritus associated with allergic dermatitis in dogs.  \nTreatment of clinical manifestations of atopic dermatitis in dogs.  \n5. CONTRAINDICATIONS  \nDo not use in case of hypersensitivity to the active substance or to any of the excipients.  \nDo not use in dogs less than 3 kg bodyweight.  \n6. SPECIAL WARNINGS  \nSpecial warnings:  \nLokivetmab may induce transient or persistent anti-drug antibodies. The induction of such antibodies is uncommon and may have no effect (transient anti-drug antibodies) or may result in a noticeable decrease in efficacy (persistent anti-drug antibodies) in animals that responded to treatment previously.  \nSpecial precautions for safe use in the target species:  \nAvoidance or elimination of the allergen is an important consideration in the successful treatment of allergic dermatitis. When treating pruritus associated with allergic dermatitis with lokivetmab, investigate and treat any underlying causes (e.g. flea allergic dermatitis, contact dermatitis, food hypersensitivity); this product is not intended to be used as a long-term maintenance therapy if the offending allergen(s) can be successfully avoided or eliminated. Furthermore, in cases of allergic dermatitis and atopic dermatitis, it is recommended to investigate and treat  \nRevised: January 2025  \nAN: 03226/2024  \ncomplicating factors, such as bacterial, fungal or parasitic infections/infestations (e.g. flea and mange) .  \nIt is recommended to monitor dogs for bacterial infections associated with atopic dermatitis, especially during the first weeks of treatment.  \nIf no","cbCaimseNRkJOvme","https://ap.wps.com/l/cbCaimseNRkJOvme","pdf",117288,9,"English","# Outer package minimum particulars\n## Name, active substances, and package size\n## Target species, indications, and route\n## Withdrawal period, expiry date, and storage\n## Required label statements and marketing authorisation holder\n## Batch number and disposal/storage restrictions\n# Small immediate packaging unit minimum particulars\n## Product name, composition, and batch/expiry\n## Route and required label statements\n# Package leaflet particulars\n## Composition and description of solution\n## Indications and contraindications\n## Special warnings and precautions for use\n## Precautions for administerer and pregnancy/lactation","[{\"question\":\"What is the active ingredient and strength in CYTOPOINT 10 mg for dogs?\",\"answer\":\"Each 1 ml dose contains 10 mg lokivetmab. The leaflet also describes it as a clear to opalescent solution without visible particles.\"},{\"question\":\"How is CYTOPOINT administered and what are the target species?\",\"answer\":\"CYTOPOINT is for dogs only and is given by subcutaneous (SC) use. The label specifies subcutaneous use for the outer package and SC for the small immediate packaging unit.\"},{\"question\":\"What are the key warnings and precautions before and during treatment?\",\"answer\":\"Lokivetmab may induce transient or persistent anti-drug antibodies, potentially reducing efficacy in some dogs. Investigate and treat underlying causes of allergic dermatitis, monitor for bacterial infections during the first weeks, and consider a second dose one month later if response is limited within one month.\"}]","CYTOPOINT 10 mg solution for injection for dogs - Package and leaflet minimum particulars - Revised January 2025 | PDF",1791867641]